JNJ Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 20.83% compared to Johnson & Johnson's net margin of 39.21%. Johnson & Johnson's return on equity of 33.27% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Johnson & Johnson has a consensus price target of $230.63, signalling downside risk potential of -0.05%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $139.46 which suggests that it could fall by -2.4%. Given that Gilead Sciences, Inc. has more downside risk than Johnson & Johnson, analysts believe Johnson & Johnson is more attractive than Gilead Sciences, Inc..

Johnson & Johnson has a beta of 0.350, which suggesting that the stock is 64.977% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.23%. Gilead Sciences, Inc. offers a yield of 2.21% to investors and pays a quarterly dividend of $0.79 per share. Johnson & Johnson pays 46.59% of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.

Johnson & Johnson quarterly revenues are $24.6B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.8B. Johnson & Johnson's net income of $5.1B is higher than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Johnson & Johnson's price-to-earnings ratio is 20.89x while Gilead Sciences, Inc.'s PE ratio is 22.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.95x versus 6.18x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 20.83% compared to Johnson & Johnson's net margin of 27.89%. Johnson & Johnson's return on equity of 33.27% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Johnson & Johnson has a consensus price target of $230.63, signalling downside risk potential of -0.05%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 23.17%. Given that Intuitive Surgical, Inc. has higher upside potential than Johnson & Johnson, analysts believe Intuitive Surgical, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.350, which suggesting that the stock is 64.977% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.23%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 46.59% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24.6B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Johnson & Johnson's net income of $5.1B is higher than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Johnson & Johnson's price-to-earnings ratio is 20.89x while Intuitive Surgical, Inc.'s PE ratio is 63.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.95x versus 17.90x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 20.83% compared to Johnson & Johnson's net margin of 31.72%. Johnson & Johnson's return on equity of 33.27% beat Eli Lilly & Co.'s return on equity of 106.26%.

Johnson & Johnson has a consensus price target of $230.63, signalling downside risk potential of -0.05%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,150.00 which suggests that it could grow by 10.14%. Given that Eli Lilly & Co. has higher upside potential than Johnson & Johnson, analysts believe Eli Lilly & Co. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.350, which suggesting that the stock is 64.977% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.23%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Johnson & Johnson pays 46.59% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24.6B, which are larger than Eli Lilly & Co. quarterly revenues of $17.6B. Johnson & Johnson's net income of $5.1B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Johnson & Johnson's price-to-earnings ratio is 20.89x while Eli Lilly & Co.'s PE ratio is 51.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.95x versus 16.02x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 20.83% compared to Johnson & Johnson's net margin of 21.74%. Johnson & Johnson's return on equity of 33.27% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Johnson & Johnson has a consensus price target of $230.63, signalling downside risk potential of -0.05%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $859.58 which suggests that it could grow by 13.85%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.350, which suggesting that the stock is 64.977% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.23%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.88 per share. Johnson & Johnson pays 46.59% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24.6B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Johnson & Johnson's net income of $5.1B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Johnson & Johnson's price-to-earnings ratio is 20.89x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.95x versus 5.72x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.